The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature

(2017) Laura Hickmott et al.   Targeted Oncology

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

(2016) Thomas K. Eigentler et al.   CANCER TREATMENT REVIEWS

Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review

(2016) M.N Joshi et al.   CLINICAL ENDOCRINOLOGY

Low level autoantibodies can be frequently detected in the general Australian population

(2016) Pooja Deshpande et al.   PATHOLOGY

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

(2015) Alexander Faje   Pituitary

Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis

(2014) Yosef Chodakiewitz et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

(2014) Mabel Ryder et al.   ENDOCRINE-RELATED CANCER

Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma

(2014) Alexander T. Faje et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy

(2013) A. Lammert et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Endocrine Side Effects Induced by Immune Checkpoint Inhibitors

(2013) Salvatore Maria Corsello et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

(2012) A. Juszczak et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease

(2012) F. Torino et al.   ONCOLOGIST

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY